1
Clinical Trials associated with Autologous NKT Cells(Beijing Cancer Hospital) / Unknown statusPhase 1IIT An Open Label, Dose Escalation, Phase I Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients
Considerable progress in the treatment of metastatic melanoma has been made in the past 5years, with the approval of immune checkpoint-blocking antibodies and agents targeting BRAF mutation. Investigators conducted a open label, dose escalation, phase I clinical trial of to explore the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of intravenous administration of autologous NKT Cells in metastatic melanoma patients.
100 Clinical Results associated with Autologous NKT Cells(Beijing Cancer Hospital)
100 Translational Medicine associated with Autologous NKT Cells(Beijing Cancer Hospital)
100 Patents (Medical) associated with Autologous NKT Cells(Beijing Cancer Hospital)
100 Deals associated with Autologous NKT Cells(Beijing Cancer Hospital)